HBM Holdings Limited (HKEX: 02142) has entered a strategic collaboration with China National Pharmaceutical Group Co., Ltd. (Sinopharm) to establish a joint biologics discovery consortium, pairing Harbour BioMed's Harbour Mice fully human antibody platform with Sinopharm's national-scale clinical development, manufacturing, and commercial infrastructure.
The arrangement — formally named the Sinopharm – Harbour BioMed Innovation Consortium — covers the full discovery-to-commercialization lifecycle across oncology, immune-mediated inflammatory diseases, and additional therapeutic areas. Harbour BioMed will drive target validation, lead antibody discovery and optimization, antibody format design, and antibody engineering using the Harbour Mice platform and AI-enabled drug discovery capabilities. Sinopharm contributes clinical execution, commercial-scale manufacturing process development, production of clinical trial materials, and downstream commercialization. Both parties will jointly fund R&D activities and share product rights under terms described only as "mutually agreed". No upfront payment, milestone structure, or royalty rates were disclosed.
The deal is structurally distinct from Harbour BioMed's recent outbound transactions. In December 2025, the company licensed the Harbour Mice heavy-chain antibody platform to Bristol Myers Squibb for multi-specific antibody discovery, receiving up to USD 90 million in upfront and research payments plus up to USD 1.035 billion in milestones. In February 2026, it out-licensed HBM4003, an anti-CTLA-4 fully human antibody, to Solstice Oncology for ex-Greater China rights in a deal carrying more than USD 105 million upfront and approximately USD 1.1 billion in potential milestones. Both transactions explicitly excluded Greater China. The Sinopharm consortium is the logical domestic counterpart — providing the clinical and commercial infrastructure needed to develop the China rights Harbour BioMed has systematically retained.
Harbour BioMed has been operating at pace across its pipeline and in BD activity. The firm has an in-house pipeline, recently announcing the initiation of a Phase II study of HBM9378/WIN378, a fully human anti-TSLP antibody for COPD — the same asset that Kelun-Biotech and Harbour BioMed licensed to Windward Bio AG for ex-Greater China rights in January 2025 in a deal worth up to USD 970 million. The company also advanced a collaboration with AstraZeneca in November 2025 to discover next-generation biotherapeutics in oncology, and in June 2026 jointly initiated MegaStream TechBio with BioMap, an AI-biology venture.